Radiocor News

Illinois jury finds GSK not liable in Zantac cancer case

Jury dismisses next Zantac trial (Il Sole 24 Ore Radiocor) - London, 24 May - The UK pharmaceutical company GlaxoSmithKline (GSK) said a jury verdict in Illinois ruled in its favor finding that the company is not liable for the plaintiff's colorectal cancer in a trial related to GSK's heartburn drug Zantac.

This was the first Zantac case to go to trial.

"This outcome is consistent with the scientific consensus that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer, supported by 16 epidemiological studies looking at human data regarding the use of ranitidine. GSK will continue to vigorously defend itself against all other claims," GSK said.

Prior to this verdict, the court rejected the plaintiff's ability to request punitive damages.

GSK also said that another Illinois court dismissed the next Zantac trial, which was due to start on Thursday, on the basis that GSK was not the brand manufacturer of over-the-counter Zantac at the time the plaintiff allegedly used it and should not be liable for any subsequent over-the-counter Zantac use.

AAA-Sch

(RADIOCOR) 24-05-24 11:04:08 (0254) 5 NNNN

 


The Exchange accepts no responsability for the content of the website you are now accessing or for any reliance placed by you or any person on the information contained on it.

By allowing this link the Exchange does not intend in any country, directly or indirectly, to solicit business or offer any securities to any person.


You will be redirected in five seconds.